Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of COT/TPL2/MAP3K8 was done on 70% confluent log phase U-87MG cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with ABfinity™ COT/TPL2/MAP3K8 (3HCLC), Recombinant Rabbit Oligoclonal Antibody (710377) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing cytoplasmic localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide corresponding to amino acids 282–293 of human COT/TPL2/MAP3K8|
|Contains||0.09% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 1 month. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1 ug/ml X 10^6 cells|
|Immunocytochemistry (ICC)||2-3 ug/ml|
|Immunofluorescence (IF)||2-3 ug/ml|
|Western Blot (WB)||2-3 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with bovine, canine, equine, mouse, rabbit and rat based on sequence homology.
ABfinity™ recombinant antibodies are rabbit monoclonal antibodies, unmatched for producing superior results. ABfinity™ antibodies are developed by immunizing animals, screening for functionality, cloning the immunogen-specific antibody genes into high-level mammalian expression vectors, produced on a large scale and purified with Protein A.
ABfinity™ oligoclonal antibodies comprise a selection of multiple different recombinant monoclonal antibodies, providing the best of both worlds—the sensitivity of a polyclonal antibody with the specificity of a monoclonal, all delivered with the consistency only found in a recombinant antibody. While functionally the same as a polyclonal antibody—recognizing multiple epitope sites on the target and producing higher detection sensitivity for low abundance targets when compared with monoclonal antibodies—an oligoclonal antibody has a known mixture of light and heavy chains. This exact population can be produced in every lot, circumventing the biological variability typically associated with polyclonal antibody production.
Intact IgG appears on a non-reducing gel as ~150 kDa band and upon reduction generating a ~25 kDa light chain band and a ~50 kDa heavy chain.
Cancer Osaka thyroid oncogene is a member of the serine threonine protein kinase family. This protein is localized in the cytoplasm, and functions to activate JNK and MAP kinase pathways. COT also activates IK-B kinases to stimulate nuclear production of NF-KappaB, mediates production of IL-2 and TNF-alpha during T cell activation, and is involved in T-cell co-stimulation, signal transduction, and amino acid phosphorylation. The COT protein is encoded by the MAP3K8 gene located on chromosome 10.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
augmented in rheumatoid arthritis 2; c-COT; cancer Osaka thyroid oncogene; cancer Osaka thyroid, oncogene; cot (cancer Osaka thyroid) oncogene; COT proto-oncogene serine/threonine-protein kinase; EST; ESTF; Ewing sarcoma transformant; MEKK8; mitogen activated protein kinase kinase kinase 8; mitogen-activated protein kinase kinase kinase 8; proto-oncogene c-Cot; proto-oncogene serine/threoine protein kinase; serine/threonine-protein kinase cot; Tpl-2; TPL2; tumor progression locus 2
AURA2; c-COT; COT; Cot/Tpl2; EST; ESTF; MAP3K8; MEKK8; Tpl-2; TPL2